Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26168070 | 0.88 | ALDH1A1 (0.50) | ALDH1A1TSHRMEN1KMT2AHPGD | |
| SCHEMBL1666014 | 0.86 | ALDH1A1 (0.56) | ALDH1A1TSHRMEN1KMT2AHPGD | |
| SCHEMBL1665641 | 0.86 | ALDH1A1 (0.56) | ALDH1A1TSHRMEN1KMT2AHPGD | |
| SCHEMBL2064880 | 0.85 | ALDH1A1 (0.58) | ALDH1A1TSHRMEN1KMT2AHPGD | |
| SCHEMBL26168090 | 0.84 | ALDH1A1 (0.46) | ALDH1A1TSHRMEN1KMT2AHPGD | |
| SCHEMBL3932101 | 0.83 | ALDH1A1 (0.53) | ALDH1A1TSHRMEN1KMT2AHPGD | |
| SCHEMBL7517585 | 0.83 | ALDH1A1 (0.51) | ALDH1A1TSHRMEN1KMT2AHPGD | |
| SCHEMBL4657134 | 0.82 | ALDH1A1 (0.59) | ALDH1A1TSHRMEN1KMT2AHPGD | |
| SCHEMBL4656956 | 0.82 | TSHR (0.52) | ALDH1A1TSHRMEN1KMT2APOLB | |
| SCHEMBL9459074 | 0.82 | ALDH1A1 (0.55) | ALDH1A1TSHRMEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127299-A1 | NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF | LG ELECTRONICS INC. (KR) | 2022-04-28 | — | — | US | disclosed |
| US-10822653-B1 | Nucleotide cleavable linkers and uses thereof | Singular Genomics Systems, Inc. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200340051-A1 | NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2020-10-29 | — | — | US | disclosed |
| US-9662335-B2 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2017-05-30 | — | — | US | disclosed |
| US-9551721-B2 | Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200340051-A1 | NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF | NUDT21, CPSF7, DCLRE1A | ALDH1A1 3019/4885TSHR 4430/4885MEN1 2454/4885 |
| US-20220127299-A1 | NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF | NUDT21, CPSF7, DCLRE1A | ALDH1A1 3019/4885TSHR 4430/4885MEN1 2454/4885 |
| US-10822653-B1 | Nucleotide cleavable linkers and uses thereof | NUDT21, CPSF7, DCLRE1A | ALDH1A1 3019/4885TSHR 4430/4885MEN1 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.